A new research collaboration reports the discovery and application of novel therapeutic strategies that selectively target EGFR and other kinases with controlled release in the tumor microenvironment to improve therapeutic efficacy, with promising results. The result is bioorganic chemistry.
The study was carried out by researchers from the University of Eastern Finland, as well as North Carolina State University in the US, the University of North Carolina at Chapel Hill in the US, and the University of Oslo in Norway.
Tyrosine kinase inhibitors (TKIs) are clinically limited by unwanted inhibition of epidermal growth factor receptor (EGFR) and other kinases in healthy tissues, causing toxicity and narrowing the therapeutic range of the drugs.
In this study, we evaluated carbamate masking of the 4-anilinoquinazoline hinge nitrogen as a scaffold-centric strategy to modulate exposure and enable controlled activation across a panel of EGFR-TKIs. ”
Christopher Asquith, Senior Researcher, Faculty of Pharmacy, University of Eastern Finland
Researchers explored the design of beta-eliminating sulfone linkers for localized release from alginate hydrogels. Hydrolytic profiling revealed that efficient parent drug release occurs only at basic pH, defining an important constraint for depot formulations in the slightly acidic tumor microenvironment. In parallel, they developed a nitroreductase (NTR)-activatable AQ-TKI prodrug. Nitroimidazole carbamates have increased polarity and tuned solubility while maintaining a favorable pharmacokinetic compound profile. All prodrugs were chemically stable under physiologically relevant conditions and underwent efficient NTR-dependent uncaging to regenerate the parent TKI.
Molecular dynamics simulations and Volz-2 protein-ligand affinity predictions showed weakened binding and reduced kinase target space for the intact prodrug compared to the parent compound, consistent with higher IC50 values in cell-free EGFR assays, supporting attenuated basal activity prior to activation. Taken together, these results establish AQ carbamate derivatization as a generalizable platform for EGFR-TKI prodrug design and provide quantitative design rules that link scaffold masking, stability, activation, and target engagement.
“Carbamate masking of 4-anilinoquinazoline TKIs allows for controlled prodrug activation, reducing EGFR binding and basal activity. This proof-of-concept study demonstrates its broad applicability to compounds used in the clinic and to compounds under investigation. This study significantly contributes to both the targeted therapy and anticancer research fields,” added Professor Joshua Pearce, North Carolina State University.
sauce:
University of Eastern Finland (UEF Communications)
Reference magazines:
Carpio, M.B. Others. (2026). 4-anilinoquinazoline carbamate derivatization as a platform for prodrug design and local drug delivery. Bioorganic chemistry. DOI: 10.1016/j.bioorg.2026.109912. https://www.sciencedirect.com/science/article/pii/S0045206826004487?via%3Dihub
